Use of the Jarvik 2000 Continuous Flow Left Ventricular Assist Device for Acute Myocardial Infarction and Cardiogenic Shock

Division of Cardiothoracic Surgery, University of North Carolina, Chapel Hill, North Carolina 27599-7065, USA.
The Journal of heart and lung transplantation: the official publication of the International Society for Heart Transplantation (Impact Factor: 6.65). 08/2007; 26(7):756-8. DOI: 10.1016/j.healun.2007.04.011
Source: PubMed


Several strategies for circulatory support have been successfully utilized as bridges to recovery or transplantation after acute myocardial infarction and cardiogenic shock. We report the novel use of a continuous flow left ventricular assist device (LVAD) for successful recovery and bridging to transplantation in a patient who had massive anterior wall myocardial infarction.

6 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: The development of a simple mapping technology for viewing the activation wavefronts of rodent hearts is currently ongoing. The successful development of an electrophysiologic (EP) electrode array biosensor for rodent hearts has been the foundation of this work. Our goal is to develop a simple method to process EP data obtained by the biosensor and present the data in a graphical format suitable for additional quantitative and qualitative analysis
    BMES/EMBS Conference, 1999. Proceedings of the First Joint; 02/1999
  • [Show abstract] [Hide abstract]
    ABSTRACT: Acute cardiogenic shock has a high mortality. The number of mechanical circulatory assist devices to encounter this life-threatening condition is steadily growing. These devices enable physicians to treat patients with acute cardiac failure refractory to conventional therapy. Mechanical circulatory assist devices are considered last resort to prevent or to reverse a cardiogenic shock. Different centrifugal, pulsatile or nonpulsatile (axial) flow pumps are available to rescue patients in different scenarios. These mechanical circulatory assist devices can be placed percutaneously or surgically as extracorporeal or intracorporeal mechanical circulatory assist devices. Percutaneous mechanical circulatory assist devices are useful to establish rapid life-saving circulatory support under different circumstances. A stabilized patient can then be transferred to an intensive care unit, a catheterization laboratory or an operating room for further assessment and additional treatment with possible change to a mid-term or long-term mechanical circulatory assist device. Percutaneous mechanical circulatory assist devices can be implanted in an emergency setting in patients with acute cardiogenic shock refractory to conventional therapy irrespective of the given location. The choice for a specific mechanical circulatory assist device should be based on the underlying condition and individualized prognosis. Based on the findings of this review, circulatory or axial-flow pumps should be considered first-line devices.
    Current opinion in cardiology 07/2008; 23(4):399-406. DOI:10.1097/HCO.0b013e328303e134 · 2.70 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The mortality of acute heart failure (AHF) remains high despite advances in treatment. Mechanical circulatory support (MCS) can be applied in AHF, refractory to conventional measures, to improve outcomes. This article aims to describe the current and the prospective role of MCS in the treatment of AHF. The support strategies and the indications of MCS are continuously evolving, including situations considered as contraindications in the past. Appropriate patient selection, advanced device technology and improved patient management have contributed to the substantially improved results. Evolution in device technology results in evolution of the clinical applications of MCS. Earlier application of MCS, with novel, flexible and individualized support strategies is now feasible. Bridging to recovery is the most intriguing support strategy and bridging to future treatments is feasible with long-term support. The progressively expanding role of MCS in the treatment of heart failure is not reflected in the existing guidelines. Being reserved for refractory heart failure, MCS has been applied to the sickest patients who were less amenable to randomization. This explains the lack of robust evidence, but also highlights the value of the progressively improving results. The anticipated wider application of MCS should be better defined, systematically recorded, and guided.
    Acute Cardiac Care 10/2009; 11(4):204-15. DOI:10.1080/17482940903177028
Show more